Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine.
about
WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients.Is there a subgroup of long-term evolution among patients with advanced lung cancer?: hints from the analysis of survival curves from cancer registry data.Indirect comparison of the efficacy and safety of gefitinib and cetuximab-based therapy in patients with advanced non-small-cell lung cancer.Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilizationImpact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patientsObservation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer.Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report.Mitochondrial pathway-mediated apoptosis is associated with erlotinib-induced cytotoxicity in hepatic cells.Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis.[Drug induced hepatotoxicity in targeted therapy for lung cancer].
P2860
Q27853174-09F65A77-4056-4905-9284-2636D43F0088Q30877384-1A293BF4-6F54-43C2-B5CE-A01DCBDBB9CCQ34608124-153F1DF8-4E58-43C3-82DE-3194DAAAE478Q35059923-6B65AA39-D10A-4C1E-9E8B-04246B153CF0Q35588356-932C5FA1-B618-4365-8997-F13BDD05E5D8Q36530038-7484F58B-5F1B-467F-8D87-6B343F204569Q37164590-91C86A6D-B9AE-4013-BF5F-762AADC98444Q41356054-20D50723-FD48-4F71-9C4A-8F780E23A689Q49727278-47D8619D-5A7D-414F-9F7D-6FE580C35E44Q54977585-46B47FBE-C976-414F-A989-42AAB4A839EDQ55071041-CD4F7615-FA42-45B2-819D-D1671A41643D
P2860
Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Long-term survival rates of pa ...... us vinorelbine or gemcitabine.
@ast
Long-term survival rates of pa ...... us vinorelbine or gemcitabine.
@en
type
label
Long-term survival rates of pa ...... us vinorelbine or gemcitabine.
@ast
Long-term survival rates of pa ...... us vinorelbine or gemcitabine.
@en
prefLabel
Long-term survival rates of pa ...... us vinorelbine or gemcitabine.
@ast
Long-term survival rates of pa ...... us vinorelbine or gemcitabine.
@en
P2093
P2860
P356
P1476
Long-term survival rates of pa ...... lus vinorelbine or gemcitabine
@en
P2093
Adem Dirican
Atilla Güven Atici
Serhat Findik
P2860
P304
P356
10.3892/ETM.2012.714
P577
2012-09-18T00:00:00Z